| Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model X Cao, ST Gibbs, L Fang, HA Miller, CP Landowski, HC Shin, ... Pharmaceutical research 23, 1675-1686, 2006 | 445 | 2006 |
| A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells T Zhang, A Hamza, X Cao, B Wang, S Yu, CG Zhan, D Sun Molecular cancer therapeutics 7 (1), 162-170, 2008 | 431 | 2008 |
| Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia X Cao, L Fang, S Gibbs, Y Huang, Z Dai, P Wen, X Zheng, W Sadee, ... Cancer chemotherapy and pharmacology 59, 495-505, 2007 | 258 | 2007 |
| Lipopolysaccharide-induced macrophage inflammatory response is regulated by SHIP H Fang, RA Pengal, X Cao, LP Ganesan, MD Wewers, CB Marsh, ... The Journal of Immunology 173 (1), 360-366, 2004 | 224 | 2004 |
| Synthesis and enzyme-specific activation of carbohydrate− geldanamycin conjugates with potent anticancer activity H Cheng, X Cao, M Xian, L Fang, TB Cai, JJ Ji, JB Tunac, D Sun, ... Journal of Medicinal chemistry 48 (2), 645-652, 2005 | 166 | 2005 |
| US FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab M Hazarika, MK Chuk, MR Theoret, S Mushti, K He, SL Weis, AH Putman, ... Clinical Cancer Research 23 (14), 3484-3488, 2017 | 134 | 2017 |
| The inositol 3-phosphatase PTEN negatively regulates Fcγ receptor signaling, but supports Toll-like receptor 4 signaling in murine peritoneal macrophages X Cao, G Wei, H Fang, J Guo, M Weinstein, CB Marsh, MC Ostrowski, ... The Journal of Immunology 172 (8), 4851-4857, 2004 | 126 | 2004 |
| Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor X Cao, M Bloomston, T Zhang, WL Frankel, G Jia, B Wang, NC Hall, ... Clinical Cancer Research 14 (6), 1831-1839, 2008 | 102 | 2008 |
| Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability X Cao, LX Yu, C Barbaciru, CP Landowski, HC Shin, S Gibbs, HA Miller, ... Molecular Pharmaceutics 2 (4), 329-340, 2005 | 87 | 2005 |
| Syntheses and biological activities of daunorubicin analogs with uncommon sugars L Zhu, X Cao, W Chen, G Zhang, D Sun, PG Wang Bioorganic & medicinal chemistry 13 (23), 6381-6387, 2005 | 71 | 2005 |
| Molecular analysis of expression and function of hFcγRIIbl and b2 isoforms in myeloid cells T Joshi, LP Ganesan, X Cao, S Tridandapani Molecular immunology 43 (7), 839-850, 2006 | 66 | 2006 |
| Alkaliphilus crotonatoxidans sp. nov., a strictly anaerobic, crotonate-dismutating bacterium isolated from a methanogenic environment X Cao, X Liu, X Dong International Journal of Systematic and Evolutionary Microbiology 53 (4 …, 2003 | 63 | 2003 |
| Pharmacokinetics and Clinical Evaluation of 125I-Radiolabeled Humanized CC49 Monoclonal Antibody (HuCC49ΔCH2) in Recurrent and Metastatic Colorectal … J Xiao, S Horst, G Hinkle, X Cao, E Kocak, J Fang, D Young, M Khazaeli, ... Cancer biotherapy & radiopharmaceuticals 20 (1), 16-26, 2005 | 52 | 2005 |
| Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model X Cao, G Jia, T Zhang, M Yang, B Wang, PA Wassenaar, H Cheng, ... Cancer chemotherapy and pharmacology 62, 985-994, 2008 | 47 | 2008 |
| FDA approval summary: TAS-102 L Marcus, SJ Lemery, S Khasar, E Wearne, WS Helms, W Yuan, K He, ... Clinical Cancer Research 23 (12), 2924-2927, 2017 | 42 | 2017 |
| SAR studies of non-zinc-chelating MMP-13 inhibitors: Improving selectivity and metabolic stability DA Gao, Z Xiong, A Heim-Riether, L Amodeo, EM August, X Cao, ... Bioorganic & medicinal chemistry letters 20 (17), 5039-5043, 2010 | 37 | 2010 |
| Population pharmacokinetics of humanized monoclonal antibody HuCC49ΔCH2 and murine antibody CC49 in colorectal cancer patients L Fang, NHG Holford, G Hinkle, X Cao, JJ Xiao, M Bloomston, S Gibbs, ... The Journal of Clinical Pharmacology 47 (2), 227-237, 2007 | 32 | 2007 |
| Drug absorption principles X Cao, L Yu, D Sun Biopharmaceutics applications in drug development, 75-100, 2008 | 28 | 2008 |
| Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof JJ Gu, DJ Ambrosi, SE Lappe, Y Li, JA Hickson, DL Haasch, S Gupta, ... US Patent 9,045,551, 2015 | 24 | 2015 |
| Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof JJ Gu, DJ Ambrosi, SE Lappe, Y Li, JA Hickson, DL Haasch, S Gupta, ... US Patent 9,163,093, 2015 | 22 | 2015 |
